Sygnature Discovery Opens Second Drug Discovery Site at Alderley Park
Sygnature Discovery has begun expanding into new state of the art laboratories at Alderley Park, Cheshire, adding Chemistry and Biology expertise to its DMPK and Translational Oncology teams already present on the site.
Creating truly integrated interdisciplinary teams, co-located in the same facility, is a cornerstone of Sygnature’s success in delivering druggable candidates into the clinic. This expansion turns Alderley Park into a second co-located, integrated site for Sygnature, aligning with our driving ethos of capitalising on the problem solving and innovative power of multidisciplinary teams.
The expansion on this internationally recognised research campus also provides the opportunity to bring up to 150 scientists into Sygnature’s integrated drug discovery solutions platform, adding to the 425 staff operating at our headquarters in BioCity, Nottingham.
Dr Simon Hirst, CEO & Founder, Sygnature Discovery, said: “This is a tremendous opportunity for Sygnature. Increasing demand for our services has driven our decision to expand, and Alderley Park, with its well-earned reputation here and internationally, provides the ideal home for our new integrated site.
“With exceptional facilities tailored to our needs, an incredible set of neighbours operating on-site, and a phenomenal talent pool for us to draw from, we are set for a bright future at Alderley Park.”
The world class science and tech campus at Alderley Park – developed and managed by Bruntwood SciTech – hosts many of the world’s top scientific research organisations, creating opportunities to reinforce our network and forge new alliances.
The “Cheshire Science Corridor” also provides a highly experienced talent pool from which Sygnature can recruit for its new laboratories. Our focus on investing in experienced scientists (over 80% of Sygnature scientists hold a PhD), while also nurturing up and coming researchers to foster a broad spectrum of ideas and capabilities, makes Alderley Park the perfect setting for future growth.
Dr Kath Mackay, Managing Director, Bruntwood SciTech – Alderley Park, said: “UK life sciences has a once-in-a-generation opportunity to establish itself as a world leader, and businesses like Sygnature Discovery will be at the forefront of that push.
“Sygnature’s expansion will enable it to better collaborate within the ecosystem of companies already based here, in turn driving innovation, and make it more attractive to the talent on offer on its doorstep. We’re proud to be playing our part in helping Sygnature deliver vital drug discovery research that will have long-lasting benefits for patients.”
For more information about our integrated drug discovery platform, explore our website, or get in touch to speak with an expert.